I don't think you can read the ceos Facebook post any other way.
This pre empts news of a partnership and most likely with Johnson and Johnson who have just had a two year setback with their viacyte clinical trials. The device and trials have to be completely redesigned.
Ciab has always been superior to viacyte but our company has done careful preparation for its trials while they rushed ahead. The tortoise and the hare.
Now Johnson and Johnson want to capture the future diabetes market which is what they thought they were doing when they bought viacyte. That's failed.. Now it's our turn.
The head of Johnson and Johnsons cancer unit was at our bio presentation. A few weeks later our CEO is in his hometown after stints in New York and Washington.
Cancer first. Then diabetes. Johnson and Johnson are the perfect partners.
Go figure.
This looks like being a very exciting few weeks for pharmacyte. Not much doubt about funding for our pancreatic cancer trials I'd think.
News 
Market Data 
Discover 
